{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T02:00:43Z","timestamp":1793152843714,"version":"4.5.0"},"reference-count":90,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,7,29]],"date-time":"2025-07-29T00:00:00Z","timestamp":1753747200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,7,29]],"date-time":"2025-07-29T00:00:00Z","timestamp":1753747200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100003718","name":"Korea Institute of Oriental Medicine","doi-asserted-by":"crossref","award":["KSN2322240"],"award-info":[{"award-number":["KSN2322240"]}],"id":[{"id":"10.13039\/501100003718","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Cancer"],"DOI":"10.1186\/s12885-025-14629-4","type":"journal-article","created":{"date-parts":[[2025,7,29]],"date-time":"2025-07-29T08:13:38Z","timestamp":1753776818000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Effects of Bojungikki-Tang on immune response and clinical outcomes in NSCLC patients receiving immune checkpoint inhibitors: a randomized pilot study"],"prefix":"10.1186","volume":"25","author":[{"given":"Mi Mi","family":"Ko","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Se Won","family":"Na","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jin-Mu","family":"Yi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ho","family":"Jang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chang Min","family":"Choi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seung Hyeun","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sung Yong","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mi-Kyung","family":"Jeong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,7,29]]},"reference":[{"key":"14629_CR1","doi-asserted-by":"publisher","first-page":"335","DOI":"10.4143\/crt.2020.206","volume":"52","author":"S Hong","year":"2020","unstructured":"Hong S, Won YJ, Park YR, Jung KW, Kong HJ, Lee ES. Community of Population-Based regional Cancer registries. Cancer statistics in korea: incidence, mortality, survival, and prevalence in 2017. Cancer Res Treat. 2020;52:335\u201350. https:\/\/doi.org\/10.4143\/crt.2020.206.","journal-title":"Cancer Res Treat"},{"key":"14629_CR2","doi-asserted-by":"publisher","first-page":"7","DOI":"10.3322\/caac.21654","volume":"71","author":"RL Siegel","year":"2021","unstructured":"Siegel RL, Miller KD, Fuchs HE, Jemal A. Cancer statistics, 2021. CA Cancer J Clin. 2021;71:7\u201333. https:\/\/doi.org\/10.3322\/caac.21654.","journal-title":"CA Cancer J Clin"},{"key":"14629_CR3","doi-asserted-by":"publisher","first-page":"89","DOI":"10.4046\/trd.2020.0134","volume":"84","author":"JG Lee","year":"2021","unstructured":"Lee JG, Kim HC, Choi CM. Recent trends of lung cancer in Korea. Tuberc Respir Dis (Seoul). 2021;84:89\u201395. https:\/\/doi.org\/10.4046\/trd.2020.0134.","journal-title":"Tuberc Respir Dis (Seoul)"},{"key":"14629_CR4","unstructured":"National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology (NCCN Guidelines\u00ae) non-small cell lung cancer (version 4, 2021). 2021. Available from: https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/nscl.pdf. Accessed 9 Jan 2023."},{"key":"14629_CR5","doi-asserted-by":"publisher","first-page":"116203","DOI":"10.1016\/j.biopha.2024.116203","volume":"171","author":"JW Cui","year":"2024","unstructured":"Cui JW, Li Y, Yang Y, Yang HK, Dong JM, Xiao ZH, et al. Tumor immunotherapy resistance: revealing the mechanism of PD-1 \/ PD-L1-mediated tumor immune escape. Biomed Pharmacother. 2024;171:116203. https:\/\/doi.org\/10.1016\/j.biopha.2024.116203.","journal-title":"Biomed Pharmacother"},{"key":"14629_CR6","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1186\/s12943-024-02023-w","volume":"23","author":"X Lin","year":"2024","unstructured":"Lin X, Kang K, Chen P, Zeng Z, Li G, Xiong W, et al. Regulatory mechanisms of PD-1\/PD-L1 in cancers. Mol Cancer. 2024;23:108. https:\/\/doi.org\/10.1186\/s12943-024-02023-w.","journal-title":"Mol Cancer"},{"key":"14629_CR7","doi-asserted-by":"publisher","first-page":"639","DOI":"10.1002\/ijc.32132","volume":"145","author":"P Arnaud-Coffin","year":"2019","unstructured":"Arnaud-Coffin P, Maillet D, Gan HK, Stelmes JJ, You B, Dalle S, et al. A systematic review of adverse events in randomized trials assessing immune checkpoint inhibitors. Int J Cancer. 2019;145:639\u201348. https:\/\/doi.org\/10.1002\/ijc.32132.","journal-title":"Int J Cancer"},{"key":"14629_CR8","doi-asserted-by":"publisher","first-page":"793","DOI":"10.4143\/crt.2021.769","volume":"54","author":"J Choi","year":"2022","unstructured":"Choi J, Yang Z, Lee J, Lee JH, Kim HK, Yong HS, et al. Usefulness of pulmonary rehabilitation in non-small cell lung cancer patients based on pulmonary function tests and muscle analysis using computed tomography images. Cancer Res Treat. 2022;54:793\u2013802. https:\/\/doi.org\/10.4143\/crt.2021.769.","journal-title":"Cancer Res Treat"},{"key":"14629_CR9","doi-asserted-by":"publisher","first-page":"1798","DOI":"10.1111\/1759-7714.13149","volume":"10","author":"K Komiya","year":"2019","unstructured":"Komiya K, Nakamura T, Abe T, Ogusu S, Nakashima C, Takahashi K, et al. Discontinuation due to immune-related adverse events is a possible predictive factor for immune checkpoint inhibitors in patients with non-small cell lung cancer. Thorac Cancer. 2019;10:1798\u2013804. https:\/\/doi.org\/10.1111\/1759-7714.13149.","journal-title":"Thorac Cancer"},{"key":"14629_CR10","doi-asserted-by":"publisher","first-page":"258","DOI":"10.3389\/fonc.2020.00258","volume":"10","author":"R Park","year":"2020","unstructured":"Park R, Lopes L, Cristancho CR, Riano IM, Saeed A. Treatment-related adverse events of combination immune checkpoint inhibitors: systematic review and meta-analysis. Front Oncol. 2020;10:258. https:\/\/doi.org\/10.3389\/fonc.2020.00258.","journal-title":"Front Oncol"},{"key":"14629_CR11","doi-asserted-by":"publisher","first-page":"7369","DOI":"10.2147\/OTT.S177318","volume":"11","author":"M Peng","year":"2018","unstructured":"Peng M, Li X, Lei G, Weng YM, Hu MX, Song QB. The efficacy and safety of immune checkpoint inhibitor combination therapy in lung cancer: a systematic review and meta-analysis. Onco Targets Ther. 2018;11:7369\u201383. https:\/\/doi.org\/10.2147\/OTT.S177318.","journal-title":"Onco Targets Ther"},{"key":"14629_CR12","doi-asserted-by":"publisher","first-page":"1733","DOI":"10.1016\/j.jtho.2018.05.004","volume":"13","author":"DR Spigel","year":"2018","unstructured":"Spigel DR, Chaft JE, Gettinger S, Chao BH, Dirix L, Schmid P, et al. FIR: efficacy, safety, and biomarker analysis of a phase II open-label study of Atezolizumab in PD-L1-selected patients with NSCLC. J Thorac Oncol. 2018;13:1733\u201342. https:\/\/doi.org\/10.1016\/j.jtho.2018.05.004.","journal-title":"J Thorac Oncol"},{"key":"14629_CR13","doi-asserted-by":"publisher","first-page":"924","DOI":"10.1016\/S1470-2045(19)30167-6","volume":"20","author":"H West","year":"2019","unstructured":"West H, McCleod M, Hussein M, Morabito A, Rittmeyer A, Conter HJ, et al. Atezolizumab in combination with carboplatin plus nab-paclitaxel chemotherapy compared with chemotherapy alone as first-line treatment for metastatic non-squamous non-small-cell lung cancer (IMpower130): a multicentre, randomised, open-label, phase 3 trial. Lancet Oncol. 2019;20:924\u201337. https:\/\/doi.org\/10.1016\/S1470-2045(19)30167-6.","journal-title":"Lancet Oncol"},{"key":"14629_CR14","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1177\/1534735410383170","volume":"9","author":"JS Jeong","year":"2010","unstructured":"Jeong JS, Ryu BH, Kim JS, Park JW, Choi WC, Yoon SW. Bojungikki-tang for cancer-related fatigue: a pilot randomized clinical trial. Integr Cancer Ther. 2010;9:331\u20138. https:\/\/doi.org\/10.1177\/1534735410383170.","journal-title":"Integr Cancer Ther"},{"key":"14629_CR15","doi-asserted-by":"publisher","first-page":"e13938","DOI":"10.1097\/MD.0000000000013938","volume":"98","author":"MK Jeong","year":"2019","unstructured":"Jeong MK, Kim YE, Kim A, Jung J, Son MJ. The herbal drug, Bu-Zhong-Yi-Qi-Tang, for the treatment of atopic dermatitis: protocol for a systematic review. Med (Baltimore). 2019;98:e13938. https:\/\/doi.org\/10.1097\/MD.0000000000013938.","journal-title":"Med (Baltimore)"},{"key":"14629_CR16","first-page":"4109","volume":"20","author":"T Kido","year":"2000","unstructured":"Kido T, Mori K, Daikuhara H, Tsuchiya H, Ishige A, Sasaki H. The protective effect of hochu-ekki-to (TJ-41), a Japanese herbal medicine, against HSV-1 infection in mitomycin C-treated mice. Anticancer Res. 2000;20:4109\u201313.","journal-title":"Anticancer Res"},{"key":"14629_CR17","first-page":"135","volume":"17","author":"JH Kim","year":"2011","unstructured":"Kim JH, Lee JK, Shin HK. Analysis of studies on Bojungikgi-tang (Buzhongyiqi-tang) to Establish the fundament for evidence based medicine (EBM). Korean J Orient Med. 2011;17:135\u201367.","journal-title":"Korean J Orient Med"},{"key":"14629_CR18","doi-asserted-by":"publisher","first-page":"5059469","DOI":"10.1155\/2018\/5059469","volume":"2018","author":"SR Park","year":"2018","unstructured":"Park SR, Kim KH, Kwun MJ, Lee JY, Won R, Han CW, et al. Differential regulation of NF-\u03baB and Nrf2 by Bojungikki-tang is associated with suppressing lung inflammation. Evid Based Complement Alternat Med. 2018;2018:5059469. https:\/\/doi.org\/10.1155\/2018\/5059469.","journal-title":"Evid Based Complement Alternat Med"},{"key":"14629_CR19","doi-asserted-by":"publisher","first-page":"16","DOI":"10.5582\/bst.2015.01019","volume":"9","author":"F Qi","year":"2015","unstructured":"Qi F, Zhao L, Zhou A, Zhang B, Li A, Wang Z, et al. The advantages of using traditional Chinese medicine as an adjunctive therapy in the whole course of cancer treatment instead of only terminal stage of cancer. BioSci Trends. 2015;9:16\u201334. https:\/\/doi.org\/10.5582\/bst.2015.01019.","journal-title":"BioSci Trends"},{"key":"14629_CR20","doi-asserted-by":"publisher","first-page":"976926","DOI":"10.1155\/2012\/976926","volume":"2012","author":"S Yae","year":"2012","unstructured":"Yae S, Takahashi F, Yae T, Yamaguchi T, Tsukada R, Koike K, et al. Hochuekkito (TJ-41), a Kampo formula, ameliorates cachexia induced by colon 26 adenocarcinoma in mice. Evid Based Complement Alternat Med. 2012;2012:976926. https:\/\/doi.org\/10.1155\/2012\/976926.","journal-title":"Evid Based Complement Alternat Med"},{"key":"14629_CR21","doi-asserted-by":"publisher","first-page":"1169","DOI":"10.1186\/s12885-024-12924-0","volume":"24","author":"E Cho","year":"2024","unstructured":"Cho E, Na SW, Jeong MK. Therapeutic and immunomodulatory effects of Bojungikki-tang on cancer: a scoping review. BMC Cancer. 2024;24:1169. https:\/\/doi.org\/10.1186\/s12885-024-12924-0.","journal-title":"BMC Cancer"},{"key":"14629_CR22","first-page":"599","volume":"32","author":"JH Lee","year":"2011","unstructured":"Lee JH, Hwang YH, Kwak DH, Kim TS, Ma JY. Single oral dose toxicity test of Bojungikgi-tang (Buzhongyiqi-tang) and fermented Bojungikgi-tang (Buzhongyiqi-tang) extracts in mice. Korean J Intern Med. 2011;32:599\u2013609.","journal-title":"Korean J Intern Med"},{"key":"14629_CR23","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1089\/107555302317371370","volume":"8","author":"H Satoh","year":"2002","unstructured":"Satoh H, Ishikawa H, Ohtsuka M, Sekizawa K. Japanese herbal medicine in patients with advanced lung cancer: prolongation of survival. J Altern Complement Med. 2002;8:107\u20138. https:\/\/doi.org\/10.1089\/107555302317371370.","journal-title":"J Altern Complement Med"},{"key":"14629_CR24","doi-asserted-by":"publisher","first-page":"1643804","DOI":"10.1155\/2019\/1643804","volume":"2019","author":"Y Shimada","year":"2019","unstructured":"Shimada Y, Fujimoto M, Nogami T, Watari H. Adverse events associated with ethical Kampo formulations: analysis of the domestic adverse-event data reports of the ministry of health, labor, and welfare in Japan. Evid Based Complement Alternat Med. 2019;2019:1643804. https:\/\/doi.org\/10.1155\/2019\/1643804.","journal-title":"Evid Based Complement Alternat Med"},{"key":"14629_CR25","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1016\/j.ctim.2018.07.003","volume":"40","author":"CY Wang","year":"2018","unstructured":"Wang CY, Huang HS, Su YC, Tu CY, Hsia TC, Huang ST. Conventional treatment integrated with Chinese herbal medicine improves the survival rate of patients with advanced non-small cell lung cancer. Complement Ther Med. 2018;40:29\u201336. https:\/\/doi.org\/10.1016\/j.ctim.2018.07.003.","journal-title":"Complement Ther Med"},{"key":"14629_CR26","doi-asserted-by":"publisher","first-page":"1181263","DOI":"10.3389\/fphar.2023.1181263","volume":"14","author":"SY Yang","year":"2023","unstructured":"Yang SY, Yi JM, Chun J, Park S, Bui TT, Yun HY, Chae JW, Jeong MK. Evaluation of the potential herb-drug interaction between Bojungikki-tang and PD-L1 immunotherapy in a syngeneic mouse model. Front Pharmacol. 2023;14:1181263. https:\/\/doi.org\/10.3389\/fphar.2023.1181263.","journal-title":"Front Pharmacol"},{"key":"14629_CR27","doi-asserted-by":"publisher","first-page":"250","DOI":"10.1038\/s41392-020-00348-8","volume":"5","author":"Y Cao","year":"2020","unstructured":"Cao Y, Wang X, Jin T, Tian Y, Dai C, Widarma C, et al. Immune checkpoint molecules in natural killer cells as potential targets for cancer immunotherapy. Signal Transduct Target Ther. 2020;5:250. https:\/\/doi.org\/10.1038\/s41392-020-00348-8.","journal-title":"Signal Transduct Target Ther"},{"key":"14629_CR28","doi-asserted-by":"publisher","first-page":"1604310","DOI":"10.3389\/fimmu.2025.1604310","volume":"16","author":"Y Liu","year":"2025","unstructured":"Liu Y, Qin D, Fu J. T lymphocyte heterogeneity in NSCLC: implications for biomarker development and therapeutic innovation. Front Immunol. 2025;16:1604310. https:\/\/doi.org\/10.3389\/fimmu.2025.1604310.","journal-title":"Front Immunol"},{"key":"14629_CR29","doi-asserted-by":"publisher","first-page":"7605057","DOI":"10.1155\/2021\/7605057","volume":"2021","author":"A Kiyomi","year":"2021","unstructured":"Kiyomi A, Matsuda A, Nara M, Yamazaki K, Imai S, Sugiura M. Immunological differences in human peripheral blood mononuclear cells treated with traditional Japanese herbal medicines hochuekkito, juzentaihoto, and ninjin\u2019yoeito from different pharmaceutical companies. Evid Based Complement Alternat Med. 2021;2021:7605057. https:\/\/doi.org\/10.1155\/2021\/7605057.","journal-title":"Evid Based Complement Alternat Med"},{"key":"14629_CR30","doi-asserted-by":"publisher","first-page":"917","DOI":"10.3389\/fphar.2020.00917","volume":"11","author":"K Kuchta","year":"2020","unstructured":"Kuchta K, Cameron S. Phytotherapy for cachexia: where do we stand? Front Pharmacol. 2020;11:917. https:\/\/doi.org\/10.3389\/fphar.2020.00917.","journal-title":"Front Pharmacol"},{"key":"14629_CR31","doi-asserted-by":"publisher","first-page":"104623","DOI":"10.1016\/j.phrs.2019.104623","volume":"152","author":"R Xu","year":"2020","unstructured":"Xu R, Wu J, Zhang X, Zou X, Li C, Wang H, et al. Modified Bu-zhong-yi-qi Decoction synergies with 5 fluorouracile to inhibits gastric cancer progress via PD-1\/PD-L1-dependent T cell immunization. Pharmacol Res. 2020;152:104623. https:\/\/doi.org\/10.1016\/j.phrs.2019.104623.","journal-title":"Pharmacol Res"},{"issue":"1","key":"14629_CR32","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1186\/s12967-025-06144-8","volume":"23","author":"B Zhang","year":"2025","unstructured":"Zhang B, Leung PC, Cho WC, Wong CK, Wang D. Targeting PI3K signaling in lung cancer: advances, challenges and therapeutic opportunities. J Transl Med. 2025;23(1):184. https:\/\/doi.org\/10.1186\/s12967-025-06144-8.","journal-title":"J Transl Med"},{"key":"14629_CR33","doi-asserted-by":"publisher","first-page":"4507","DOI":"10.3390\/ijerph20054507","volume":"20","author":"MM Ko","year":"2023","unstructured":"Ko MM, Jeong MK, Choi CM, Lee SH, Chun J, Yi JM, et al. Safety and efficacy of Bojungikki-Tang in advanced NSCLC patients receiving treatment with immune checkpoint inhibitors: protocol for a multicenter, double-blind, randomized, placebo-controlled pilot trial. Int J Environ Res Public Health. 2023;20:4507. https:\/\/doi.org\/10.3390\/ijerph20054507.","journal-title":"Int J Environ Res Public Health"},{"key":"14629_CR34","doi-asserted-by":"publisher","first-page":"1328","DOI":"10.1056\/NEJMoa1917346","volume":"383","author":"RS Herbst","year":"2020","unstructured":"Herbst RS, Giaccone G, de Marinis F, Reinmuth N, Vergnenegre A, Barrios CH, et al. Atezolizumab for first-line treatment of PD-L1-selected patients with NSCLC. N Engl J Med. 2020;383:1328\u201339. https:\/\/doi.org\/10.1056\/NEJMoa1917346.","journal-title":"N Engl J Med"},{"key":"14629_CR35","unstructured":"United States Department of Health and Human Services. Common Terminology Criteria for Adverse Events (CTCAE), version 4.03. National Institutes of Health\u2013 National Cancer Institute. 2010. Available from: https:\/\/evs.nci.nih.gov\/ftp1\/CTCAE\/CTCAE_4.03_2010-06-14_QuickReference_8.5x11.pdf. Accessed 9 Jan 2023."},{"key":"14629_CR36","doi-asserted-by":"publisher","first-page":"1837","DOI":"10.1016\/S0140-6736(16)00587-0","volume":"387","author":"L Fehrenbacher","year":"2016","unstructured":"Fehrenbacher L, Spira A, Ballinger M, Kowanetz M, Vansteenkiste J, Mazieres J, et al. Atezolizumab versus docetaxel for patients with previously treated non-small-cell lung cancer (Poplar): a multicentre, open-label, phase 2 randomised controlled trial. Lancet. 2016;387:1837\u201346. https:\/\/doi.org\/10.1016\/S0140-6736(16)00587-0.","journal-title":"Lancet"},{"key":"14629_CR37","doi-asserted-by":"publisher","first-page":"2288","DOI":"10.1056\/NEJMoa1716948","volume":"378","author":"MA Socinski","year":"2018","unstructured":"Socinski MA, Jotte RM, Cappuzzo F, Orlandi F, Stroyakovskiy D, Nogami N, et al. Atezolizumab for first-line treatment of metastatic nonsquamous NSCLC. N Engl J Med. 2018;378:2288\u2013301. https:\/\/doi.org\/10.1056\/NEJMoa1716948.","journal-title":"N Engl J Med"},{"key":"14629_CR38","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1186\/1477-7525-1-79","volume":"1","author":"K Webster","year":"2003","unstructured":"Webster K, Cella D, Yost K. The functional assessment of chronic illness therapy (FACIT) measurement system: properties, applications, and interpretation. Health Qual Life Outcomes. 2003;1:79. https:\/\/doi.org\/10.1186\/1477-7525-1-79.","journal-title":"Health Qual Life Outcomes"},{"key":"14629_CR39","unstructured":"Fayers P, Aaronson NK, Bjordal K, Groenvold M, Curran D, Bottomley A. EORTC QLQ-C30 scoring manual. 3rd ed. European Organization for Research and Treatment of Cancer; 2001."},{"key":"14629_CR40","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1093\/annonc\/mdn537","volume":"20","author":"O Minton","year":"2009","unstructured":"Minton O, Stone P. A systematic review of the scales used for the measurement of cancer-related fatigue (CRF). Ann Oncol. 2009;20:17\u201325. https:\/\/doi.org\/10.1093\/annonc\/mdn537.","journal-title":"Ann Oncol"},{"key":"14629_CR41","doi-asserted-by":"publisher","first-page":"1861","DOI":"10.1093\/annonc\/mdm349","volume":"18","author":"DJ Storey","year":"2007","unstructured":"Storey DJ, Waters RA, Hibberd CJ, Rush RW, Cargill AT, Wall LR, et al. Clinically relevant fatigue in cancer outpatients: the Edinburgh Cancer centre symptom study. Ann Oncol. 2007;18:1861\u20139. https:\/\/doi.org\/10.1093\/annonc\/mdm349.","journal-title":"Ann Oncol"},{"key":"14629_CR42","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1016\/j.jamda.2017.07.006","volume":"19","author":"S Kim","year":"2018","unstructured":"Kim S, Kim M, Won CW. Validation of the Korean version of the SARC-F questionnaire to assess sarcopenia: Korean frailty and aging cohort study. J Am Med Dir Assoc. 2018;19:40\u2013e51. https:\/\/doi.org\/10.1016\/j.jamda.2017.07.006.","journal-title":"J Am Med Dir Assoc"},{"key":"14629_CR43","doi-asserted-by":"publisher","first-page":"17","DOI":"10.15188\/JPPKM.2016.04.30.2.116","volume":"20","author":"KH Bae","year":"2016","unstructured":"Bae KH, Yoon Y, Yeo M, Kim HS, Lee YM, Lee S. Development on the questionnaire of cold-heat pattern identification based on usual symptoms for health promotion-focused on agreement study. J Soc Prev Korean Med. 2016;20:17\u201326. https:\/\/doi.org\/10.15188\/JPPKM.2016.04.30.2.116.","journal-title":"J Soc Prev Korean Med"},{"key":"14629_CR44","doi-asserted-by":"publisher","first-page":"116","DOI":"10.15188\/kjopp.2016.04.30.2.116","volume":"30","author":"M Yeo","year":"2016","unstructured":"Yeo M, Park K, Bae K, Jang ES, Lee YS. Development on the questionnaire of cold-heat pattern identification based on usual symptoms for health promotion\u2013 focused on reliability study. J Physiol Pathol Korean Med. 2016;30:116\u201323. https:\/\/doi.org\/10.15188\/kjopp.2016.04.30.2.116.","journal-title":"J Physiol Pathol Korean Med"},{"key":"14629_CR45","doi-asserted-by":"publisher","first-page":"176","DOI":"10.3389\/fphar.2015.00176","volume":"6","author":"K Yamaguchi","year":"2015","unstructured":"Yamaguchi K. Traditional Japanese herbal medicines for treatment of odontopathy. Front Pharmacol. 2015;6:176. https:\/\/doi.org\/10.3389\/fphar.2015.00176.","journal-title":"Front Pharmacol"},{"key":"14629_CR46","doi-asserted-by":"publisher","first-page":"2701","DOI":"10.1016\/j.immuni.2021.11.015","volume":"54","author":"DY Oh","year":"2021","unstructured":"Oh DY, Fong L. Cytotoxic CD4\u2009+\u2009T cells in cancer: expanding the immune effector toolbox. Immunity. 2021;54:2701\u201311. https:\/\/doi.org\/10.1016\/j.immuni.2021.11.015.","journal-title":"Immunity"},{"key":"14629_CR47","doi-asserted-by":"publisher","first-page":"e390","DOI":"10.1002\/mco2.390","volume":"4","author":"L Xie","year":"2023","unstructured":"Xie L, Fang J, Yu J, Zhang W, He Z, Ye L, et al. The role of CD4\u2009+\u2009T cells in tumor and chronic viral immune responses. Med. 2023;4:e390. https:\/\/doi.org\/10.1002\/mco2.390.","journal-title":"Med"},{"key":"14629_CR48","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1016\/j.cpt.2022.12.002","volume":"1","author":"H Ahmed","year":"2023","unstructured":"Ahmed H, Mahmud AR, Siddiquee MFR, Shahriar A, Biswas P, Shimul MEK, et al. Role of T cells in cancer immunotherapy: opportunities and challenges. Cancer Pathog Ther. 2023;1:116\u201326. https:\/\/doi.org\/10.1016\/j.cpt.2022.12.002.","journal-title":"Cancer Pathog Ther"},{"key":"14629_CR49","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1038\/s41392-021-00658-5","volume":"6","author":"H Zhao","year":"2021","unstructured":"Zhao H, Wu L, Yan G, Chen Y, Zhou M, Wu Y, et al. Inflammation and tumor progression: signaling pathways and targeted intervention. Signal Transduct Target Ther. 2021;6:263. https:\/\/doi.org\/10.1038\/s41392-021-00658-5.","journal-title":"Signal Transduct Target Ther"},{"key":"14629_CR50","doi-asserted-by":"publisher","first-page":"244","DOI":"10.1016\/j.intimp.2016.03.009","volume":"34","author":"X Chen","year":"2016","unstructured":"Chen X, Du Y, Lin X, Qian Y, Zhou T, Huang Z. CD4\u2009+\u2009CD25\u2009+\u2009regulatory T cells in tumor immunity. Int Immunopharmacol. 2016;34:244\u20139. https:\/\/doi.org\/10.1016\/j.intimp.2016.03.009.","journal-title":"Int Immunopharmacol"},{"key":"14629_CR51","doi-asserted-by":"publisher","first-page":"e1792","DOI":"10.1038\/cddis.2015.162","volume":"6","author":"Y Jiang","year":"2015","unstructured":"Jiang Y, Li Y, Zhu B. T-cell exhaustion in the tumor microenvironment. Cell Death Dis. 2015;6:e1792. https:\/\/doi.org\/10.1038\/cddis.2015.162.","journal-title":"Cell Death Dis"},{"key":"14629_CR52","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1158\/1078-0432.CCR-17-2156","volume":"24","author":"G Mazzaschi","year":"2018","unstructured":"Mazzaschi G, Madeddu D, Falco A, Bocchialini G, Goldoni M, Sogni F, et al. Low PD-1 expression in cytotoxic CD8\u2009+\u2009tumor-infiltrating lymphocytes confers an immune-privileged tissue microenvironment in NSCLC with a prognostic and predictive value. Clin Cancer Res. 2018;24:407\u201319. https:\/\/doi.org\/10.1158\/1078-0432.CCR-17-2156.","journal-title":"Clin Cancer Res"},{"issue":"5","key":"14629_CR53","doi-asserted-by":"publisher","first-page":"636","DOI":"10.3390\/ph17050636","volume":"17","author":"Z He","year":"2024","unstructured":"He Z, Liu X, Qin S, Yang Q, Na J, Xue Z, Zhong L. Anticancer mechanism of Astragalus polysaccharide and its application in Cancer immunotherapy. Pharmaceuticals (Basel). 2024;17(5):636. https:\/\/doi.org\/10.3390\/ph17050636.","journal-title":"Pharmaceuticals (Basel)"},{"issue":"4","key":"14629_CR54","doi-asserted-by":"publisher","first-page":"1333","DOI":"10.3892\/or.2020.7728","volume":"44","author":"S Hong","year":"2020","unstructured":"Hong S, Cai W, Huang Z, Wang Y, Mi X, Huang Y, Lin Z, Chen X. Ginsenoside Rg3 enhances the anticancer effect of 5 FU in colon cancer cells via the PI3K\/AKT pathway. Oncol Rep. 2020;44(4):1333\u201342. https:\/\/doi.org\/10.3892\/or.2020.7728.","journal-title":"Oncol Rep"},{"key":"14629_CR55","doi-asserted-by":"publisher","first-page":"5742","DOI":"10.1158\/1078-0432.CCR-21-0206","volume":"27","author":"AM Miggelbrink","year":"2021","unstructured":"Miggelbrink AM, Jackson JD, Lorrey SJ, Srinivasan ES, Waibl-Polania J, Wilkinson DS, Fecci PE. CD4 T-cell exhaustion: does it exist and what are its roles in cancer? Clin Cancer Res. 2021;27:5742\u201352. https:\/\/doi.org\/10.1158\/1078-0432.CCR-21-0206.","journal-title":"Clin Cancer Res"},{"key":"14629_CR56","doi-asserted-by":"publisher","first-page":"56233","DOI":"10.18632\/oncotarget.9316","volume":"7","author":"H Zheng","year":"2016","unstructured":"Zheng H, Liu X, Zhang J, Rice SJ, Wagman M, Kong Y, et al. Expression of PD-1 on CD4\u2009+\u2009T cells in peripheral blood associates with poor clinical outcome in non-small cell lung cancer. Oncotarget. 2016;7:56233\u201340. https:\/\/doi.org\/10.18632\/oncotarget.9316.","journal-title":"Oncotarget"},{"key":"14629_CR57","doi-asserted-by":"publisher","first-page":"1662","DOI":"10.1016\/j.ccell.2023.08.001","volume":"41","author":"G Escobar","year":"2023","unstructured":"Escobar G, Tooley K, Oliveras JP, Huang L, Cheng H, Bookstaver ML, et al. Tumor immunogenicity dictates reliance on TCF1 in CD8\u2009+\u2009T cells for response to immunotherapy. Cancer Cell. 2023;41:1662\u2013e797. https:\/\/doi.org\/10.1016\/j.ccell.2023.08.001.","journal-title":"Cancer Cell"},{"key":"14629_CR58","doi-asserted-by":"publisher","first-page":"515","DOI":"10.3390\/cancers13030515","volume":"13","author":"S Jung","year":"2021","unstructured":"Jung S, Baek JH. The potential of T cell factor 1 in sustaining CD8\u2009+\u2009T Lymphocyte-directed anti-tumor immunity. Cancers (Basel). 2021;13:515. https:\/\/doi.org\/10.3390\/cancers13030515.","journal-title":"Cancers (Basel)"},{"key":"14629_CR59","doi-asserted-by":"publisher","first-page":"240","DOI":"10.1186\/s12967-022-03437-0","volume":"20","author":"J Chu","year":"2022","unstructured":"Chu J, Gao F, Yan M, Zhao S, Yan Z, Shi B, et al. Natural killer cells: a promising immunotherapy for cancer. J Transl Med. 2022;20:240. https:\/\/doi.org\/10.1186\/s12967-022-03437-0.","journal-title":"J Transl Med"},{"key":"14629_CR60","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1158\/2159-8290.CD-20-0655","volume":"11","author":"B C\u00f3zar","year":"2021","unstructured":"C\u00f3zar B, Greppi M, Carpentier S, Narni-Mancinelli E, Chiossone L, Vivier E. Tumor-infiltrating natural killer cells. Cancer Discov. 2021;11:34\u201344. https:\/\/doi.org\/10.1158\/2159-8290.CD-20-0655.","journal-title":"Cancer Discov"},{"key":"14629_CR61","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1186\/s13045-020-01014-w","volume":"14","author":"S Liu","year":"2021","unstructured":"Liu S, Galat V, Galat Y, Lee YKA, Wainwright D, Wu J. NK cell-based cancer immunotherapy: from basic biology to clinical development. J Hematol Oncol. 2021;14:7. https:\/\/doi.org\/10.1186\/s13045-020-01014-w.","journal-title":"J Hematol Oncol"},{"key":"14629_CR62","doi-asserted-by":"publisher","first-page":"1013","DOI":"10.1136\/jitc-2022-SITC2022.1013","volume":"10","author":"L Nederby","year":"2022","unstructured":"Nederby L, Wen S, Nyhus C, Bertelsen L, Andersen R, Jakobsen A, Hansen T. Prognostic value of natural killer cell activity and derived neutrophils-to-lymphocytes ratio in non-small cell lung cancer patients receiving immune checkpoint inhibitors. J Immunother Cancer. 2022;10:1013. https:\/\/doi.org\/10.1136\/jitc-2022-SITC2022.1013.","journal-title":"J Immunother Cancer"},{"key":"14629_CR63","doi-asserted-by":"publisher","first-page":"901563","DOI":"10.3389\/fphar.2022.901563","volume":"13","author":"J Chun","year":"2022","unstructured":"Chun J, Park SM, Yi JM, Ha IJ, Kang HN, Jeong MK. Bojungikki-tang improves response to PD-L1 immunotherapy by regulating the tumor microenvironment in MC38 tumor-bearing mice. Front Pharmacol. 2022;13:901563. https:\/\/doi.org\/10.3389\/fphar.2022.901563.","journal-title":"Front Pharmacol"},{"key":"14629_CR64","doi-asserted-by":"publisher","first-page":"1246","DOI":"10.3390\/life14101246","volume":"14","author":"SW Na","year":"2024","unstructured":"Na SW, Yi JM, Yeo H, Park SM, Jeong M, Chun J, Jeong MK. Bojungikki-tang augments pembrolizumab efficacy in human PBMC-injected H460 tumor-bearing mice. Life (Basel). 2024;14:1246. https:\/\/doi.org\/10.3390\/life14101246.","journal-title":"Life (Basel)"},{"key":"14629_CR65","doi-asserted-by":"publisher","first-page":"621","DOI":"10.1007\/s40291-018-0355-7","volume":"22","author":"D Pastuszak-Lewandoska","year":"2018","unstructured":"Pastuszak-Lewandoska D, Doma\u0144ska-Senderowska D, Antczak A, Kordiak J, G\u00f3rski P, Czarnecka KH, et al. The expression levels of IL-4\/IL-13\/STAT6 signaling pathway genes and SOCS3 could help to differentiate the histopathological subtypes of non-small cell lung carcinoma. Mol Diagn Ther. 2018;22:621\u20139. https:\/\/doi.org\/10.1007\/s40291-018-0355-7.","journal-title":"Mol Diagn Ther"},{"key":"14629_CR66","doi-asserted-by":"publisher","first-page":"1635","DOI":"10.1038\/s41375-022-01572-7","volume":"36","author":"MJ Cox","year":"2022","unstructured":"Cox MJ, Manriquez Roman C, Tapper EE, Siegler EL, Chappell D, Durrant C, et al. GM-CSF disruption in CART cells modulates T cell activation and enhances CART cell anti-tumor activity. Leukemia. 2022;36:1635\u201345. https:\/\/doi.org\/10.1038\/s41375-022-01572-7.","journal-title":"Leukemia"},{"key":"14629_CR67","doi-asserted-by":"publisher","first-page":"1534","DOI":"10.1007\/s00262-006-0149-3","volume":"55","author":"A Nath","year":"2006","unstructured":"Nath A, Chattopadhya S, Chattopadhyay U, Sharma NK. Macrophage inflammatory protein (MIP)-1alpha and MIP-1beta differentially regulate release of inflammatory cytokines and generation of tumoricidal monocytes in malignancy. Cancer Immunol Immunother. 2006;55:1534\u201341. https:\/\/doi.org\/10.1007\/s00262-006-0149-3.","journal-title":"Cancer Immunol Immunother"},{"key":"14629_CR68","doi-asserted-by":"publisher","first-page":"4055","DOI":"10.1002\/cam4.2256","volume":"8","author":"PY Xing","year":"2019","unstructured":"Xing PY, Zhu YX, Wang L, Hui ZG, Liu SM, Ren JS, et al. What are the clinical symptoms and physical signs for non-small cell lung cancer before diagnosis is made? A nation-wide multicenter 10-year retrospective study in China. Cancer Med. 2019;8:4055\u201369. https:\/\/doi.org\/10.1002\/cam4.2256.","journal-title":"Cancer Med"},{"key":"14629_CR69","doi-asserted-by":"publisher","first-page":"597","DOI":"10.1038\/nrclinonc.2014.127","volume":"11","author":"JE Bower","year":"2014","unstructured":"Bower JE. Cancer-related fatigue\u2014mechanisms, risk factors, and treatments. Nat Rev Clin Oncol. 2014;11:597\u2013609. https:\/\/doi.org\/10.1038\/nrclinonc.2014.127.","journal-title":"Nat Rev Clin Oncol"},{"key":"14629_CR70","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1002\/cncr.31790","volume":"125","author":"JE Bower","year":"2019","unstructured":"Bower JE. The role of neuro-immune interactions in cancer-related fatigue: biobehavioral risk factors and mechanisms. Cancer. 2019;125:353\u201364. https:\/\/doi.org\/10.1002\/cncr.31790.","journal-title":"Cancer"},{"key":"14629_CR71","doi-asserted-by":"publisher","unstructured":"Bower JE, Lamkin DM, Suppl. S48\u201357. doi:https:\/\/doi.org\/10.1016\/j.bbi.2012.06.011.","DOI":"10.1016\/j.bbi.2012.06.011"},{"key":"14629_CR72","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1016\/j.jpainsymman.2010.11.005","volume":"42","author":"AL Cheville","year":"2011","unstructured":"Cheville AL, Novotny PJ, Sloan JA, Basford JR, Wampfler JA, Garces YI, et al. The value of a symptom cluster of fatigue, dyspnea, and cough in predicting clinical outcomes in lung cancer survivors. J Pain Symptom Manage. 2011;42:213\u201321. https:\/\/doi.org\/10.1016\/j.jpainsymman.2010.11.005.","journal-title":"J Pain Symptom Manage"},{"key":"14629_CR73","doi-asserted-by":"publisher","first-page":"2321","DOI":"10.3390\/ijms21072321","volume":"21","author":"GWPD Fonseca","year":"2020","unstructured":"Fonseca GWPD, Farkas J, Dora E, von Haehling S, Lainscak M. Cancer cachexia and related metabolic dysfunction. Int J Mol Sci. 2020;21:2321. https:\/\/doi.org\/10.3390\/ijms21072321.","journal-title":"Int J Mol Sci"},{"key":"14629_CR74","doi-asserted-by":"publisher","first-page":"971295","DOI":"10.3389\/fpain.2022.971295","volume":"3","author":"ML Law","year":"2022","unstructured":"Law ML. Cancer cachexia: pathophysiology and association with cancer-related pain. Front Pain Res (Lausanne). 2022;3:971295. https:\/\/doi.org\/10.3389\/fpain.2022.971295.","journal-title":"Front Pain Res (Lausanne)"},{"key":"14629_CR75","doi-asserted-by":"publisher","first-page":"2447","DOI":"10.1038\/s41598-019-39120-6","volume":"9","author":"T Shiroyama","year":"2019","unstructured":"Shiroyama T, Nagatomo I, Koyama S, Hirata H, Nishida S, Miyake K, et al. Impact of sarcopenia in patients with advanced non-small cell lung cancer treated with PD-1 inhibitors: a preliminary retrospective study. Sci Rep. 2019;9:2447. https:\/\/doi.org\/10.1038\/s41598-019-39120-6.","journal-title":"Sci Rep"},{"key":"14629_CR76","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1016\/s0885-3924(02)00376-7","volume":"23","author":"K Tanaka","year":"2002","unstructured":"Tanaka K, Akechi T, Okuyama T, Nishiwaki Y, Uchitomi Y. Impact of dyspnea, pain, and fatigue on daily life activities in ambulatory patients with advanced lung cancer. J Pain Symptom Manage. 2002;23:417\u201323. https:\/\/doi.org\/10.1016\/s0885-3924(02)00376-7.","journal-title":"J Pain Symptom Manage"},{"key":"14629_CR77","doi-asserted-by":"publisher","first-page":"CD004310","DOI":"10.1002\/14651858.CD004310.pub3","volume":"2013","author":"V Ruiz Garcia","year":"2013","unstructured":"Ruiz Garcia V, L\u00f3pez-Briz E, Carbonell Sanchis R, Gonzalvez Perales JL, Bort-Marti S. Megestrol acetate for treatment of anorexia-cachexia syndrome. Cochrane Database Syst Rev. 2013;2013:CD004310. https:\/\/doi.org\/10.1002\/14651858.CD004310.pub3.","journal-title":"Cochrane Database Syst Rev"},{"key":"14629_CR78","doi-asserted-by":"publisher","first-page":"1185","DOI":"10.1186\/s12885-020-07690-8","volume":"20","author":"WM Brueckl","year":"2020","unstructured":"Brueckl WM, Ficker JH, Zeitler G. Clinically relevant prognostic and predictive markers for immune-checkpoint-inhibitor (ICI) therapy in non-small cell lung cancer (NSCLC). BMC Cancer. 2020;20:1185. https:\/\/doi.org\/10.1186\/s12885-020-07690-8.","journal-title":"BMC Cancer"},{"key":"14629_CR79","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1186\/s12885-023-10649-0","volume":"23","author":"L Pang","year":"2023","unstructured":"Pang L, Xie M, Ma X, Huang A, Song J, Yao J, et al. Clinical characteristics and therapeutic effects of checkpoint inhibitor-related pneumonitis in patients with non-small cell lung cancer. BMC Cancer. 2023;23:203. https:\/\/doi.org\/10.1186\/s12885-023-10649-0.","journal-title":"BMC Cancer"},{"key":"14629_CR80","doi-asserted-by":"publisher","first-page":"783923","DOI":"10.1155\/2012\/783923","volume":"2012","author":"Z Chen","year":"2012","unstructured":"Chen Z, Wang P. Clinical distribution and molecular basis of traditional Chinese medicine ZHENG in cancer. Evid Based Complement Alternat Med. 2012;2012:783923. https:\/\/doi.org\/10.1155\/2012\/783923.","journal-title":"Evid Based Complement Alternat Med"},{"key":"14629_CR81","doi-asserted-by":"publisher","first-page":"635702","DOI":"10.1155\/2012\/635702","volume":"2012","author":"Z Chen","year":"2012","unstructured":"Chen Z, Chen LY, Wang P, Dai HY, Gao S, Wang K. Tumor microenvironment varies under different TCM ZHENG models and correlates with treatment response to herbal medicine. Evid Based Complement Alternat Med. 2012;2012:635702. https:\/\/doi.org\/10.1155\/2012\/635702.","journal-title":"Evid Based Complement Alternat Med"},{"key":"14629_CR82","doi-asserted-by":"publisher","first-page":"9920469","DOI":"10.1155\/2021\/9920469","volume":"2021","author":"Y Choi","year":"2021","unstructured":"Choi Y, Kwon O, Choi CM, Jeong MK. A pilot study of whether the cold-heat syndrome type is associated with treatment response and immune status in patients with non-small cell lung cancer. Evid Based Complement Alternat Med. 2021;2021:9920469. https:\/\/doi.org\/10.1155\/2021\/9920469.","journal-title":"Evid Based Complement Alternat Med"},{"key":"14629_CR83","doi-asserted-by":"publisher","first-page":"4275","DOI":"10.3390\/jcm11154275","volume":"11","author":"MK Jeong","year":"2022","unstructured":"Jeong MK, Chun J, Oh IJ. Novel biomarkers in lung cancer and chronic lung diseases: from the systematic perspective of Yin\u2013Yang balance. J Clin Med. 2022;11:4275. https:\/\/doi.org\/10.3390\/jcm11154275.","journal-title":"J Clin Med"},{"issue":"7","key":"14629_CR84","doi-asserted-by":"publisher","first-page":"e68742","DOI":"10.1371\/journal.pone.0068742","volume":"8","author":"W Xu","year":"2013","unstructured":"Xu W, Banerji S, Davie JR, Kassie F, Yee D, Kratzke R. Yin yang gene expression ratio signature for lung cancer prognosis. PLoS One. 2013;8(7):e68742. https:\/\/doi.org\/10.1371\/journal.pone.0068742.","journal-title":"PLoS One"},{"key":"14629_CR85","doi-asserted-by":"publisher","unstructured":"Park JH, Kwag E, Jeong MK, Park SJ, Lee S, Yoo HS. Genome-wide analysis identified SEMA4D, novel candidate gene for temperature sensitivity in patients with non-small cell lung cancer. Integr Cancer Ther. 2024;23. https:\/\/doi.org\/10.1177\/15347354241233544.","DOI":"10.1177\/15347354241233544"},{"issue":"2","key":"14629_CR86","doi-asserted-by":"publisher","first-page":"205","DOI":"10.20892\/j.issn.2095-3941.2018.0141","volume":"16","author":"X Ren","year":"2019","unstructured":"Ren X. Immunosuppressive checkpoint Siglec-15: a vital new piece of the cancer immunotherapy Jigsaw puzzle. Cancer Biol Med. 2019;16(2):205\u201310. https:\/\/doi.org\/10.20892\/j.issn.2095-3941.2018.0141.","journal-title":"Cancer Biol Med"},{"issue":"4","key":"14629_CR87","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1158\/2326-6066.CIR-13-0118","volume":"1","author":"EA Repasky","year":"2013","unstructured":"Repasky EA, Evans SS, Dewhirst MW. Temperature matters! And why it should matter to tumor immunologists. Cancer Immunol Res. 2013;1(4):210\u20136. https:\/\/doi.org\/10.1158\/2326-6066.CIR-13-0118.","journal-title":"Cancer Immunol Res"},{"issue":"2","key":"14629_CR88","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1272\/jnms.JNMS.2022_89-222","volume":"89","author":"YJ Motoo","year":"2022","unstructured":"Motoo YJ. Role of Kampo medicine in modern Cancer therapy: towards completion of standard treatment. Nippon Med Sch. 2022;89(2):139\u201344. https:\/\/doi.org\/10.1272\/jnms.JNMS.2022_89-222.","journal-title":"Nippon Med Sch"},{"issue":"3","key":"14629_CR89","doi-asserted-by":"publisher","first-page":"770","DOI":"10.1016\/j.jep.2013.04.055","volume":"148","author":"F Liang","year":"2013","unstructured":"Liang F, Li L, Wang M, Niu X, Zhan J, He X, Yu C, Jiang M, Lu A. Molecular network and chemical fragment-based characteristics of medicinal herbs with cold and hot properties from Chinese medicine. J Ethnopharmacol. 2013;148(3):770\u20139. https:\/\/doi.org\/10.1016\/j.jep.2013.04.055.","journal-title":"J Ethnopharmacol"},{"key":"14629_CR90","doi-asserted-by":"publisher","unstructured":"Cho E, Yi JM, Chun J, Jang H, Yoon SH, Lee SH, Jang SH, Park DW, Kim SJ, Um SW, Lee SY, Jeong MK. Efficacy and safety of herbal medicine Bojungikki-Tang in combination with pembrolizumab versus pembrolizumab monotherapy for stage IV non-small cell lung cancer: study protocol for a randomized, open-label, double-arm, multicenter trial. Integr Cancer Ther. 2025;24. https:\/\/doi.org\/10.1177\/15347354251319339.","DOI":"10.1177\/15347354251319339"}],"container-title":["BMC Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-025-14629-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12885-025-14629-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-025-14629-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,30]],"date-time":"2025-07-30T23:06:49Z","timestamp":1753916809000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmccancer.biomedcentral.com\/articles\/10.1186\/s12885-025-14629-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,29]]},"references-count":90,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["14629"],"URL":"https:\/\/doi.org\/10.1186\/s12885-025-14629-4","relation":{},"ISSN":["1471-2407"],"issn-type":[{"value":"1471-2407","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,29]]},"assertion":[{"value":"27 May 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 July 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 July 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was approved by the Institutional Review Boards of Korea University Guro Hospital (approval number: 2021GR0472), Asan Medical Center (approval number: S2021-2096- 0001), and Kyung Hee University Hospital (approval number: KHUH2021-08-079- 001) on September 30, 2021. The trial was registered with the Clinical Research Information Service (\n                      \n                      ; identifier number: KCT0006689) in October 2021. Informed consent was obtained from all subjects involved in the study. All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and\/or national research committee.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"1229"}}